BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26429162)

  • 1. Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
    Szántó A; Pap Z; Dénes L; Benedek Lázár E; Horváth A; Tunyogi AB; Baróti BÁ; Pávai Z
    Rom J Morphol Embryol; 2015; 56(2 Suppl):703-7. PubMed ID: 26429162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
    Varma N; Anand MS; Varma S; Juneja SS
    Leuk Lymphoma; 2011 Apr; 52(4):687-93. PubMed ID: 21314483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
    Schnittger S; Bacher U; Kern W; Tschulik C; Weiss T; Haferlach C; Haferlach T
    Br J Haematol; 2009 Sep; 146(6):665-8. PubMed ID: 19624538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
    Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
    Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center.
    Szántó A; Pap Z; Benedek I; Benedek-Lázár E; Köpeczi JB; Tunyogi AB; Vasile K; Horváth E; Pávai Z
    Rom J Morphol Embryol; 2013; 54(1):37-42. PubMed ID: 23529307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
    Na IK; Kreuzer KA; Lupberger J; Dörken B; le Coutre P
    Leuk Res; 2005 Mar; 29(3):343-5. PubMed ID: 15661271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia].
    Cao XS; Gu WY; Chen ZX; Hu SY; He J; Cen JN
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):277-9. PubMed ID: 17637262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.
    Lopotová T; Polák J; Schwarz J; Klamová H; Moravcová J
    Blood Cells Mol Dis; 2012 Jun; 49(1):41-7. PubMed ID: 22555024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
    Moumen A; Dehbi H; Kottwitz D; El Amrani M; Bouchoutrouch N; El Hadi H; Quessar A; Benchekroun S; Nadifi S; Sefrioui H
    Genet Mol Res; 2015 Feb; 14(1):1044-55. PubMed ID: 25730044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Wang ZD; Li D; Huang XJ
    Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time quantification for BCR-ABL transcripts in chronic myeloid leukaemia patients in UKMMC, Malaysia.
    Wong FL; Hamidah NH; Hawa AA; Nurul AN; Leong CF; Saw F; Ainoon O
    Malays J Pathol; 2011 Dec; 33(2):107-12. PubMed ID: 22299211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-time PCR quantification of bcr/abl chimera and WT1 genes in chronic myeloid leukemia].
    Fujii T; Inoue S; Karashima T; Masumoto M; Yamaguchi H; Kinoshita S; Muta K; Hamasaki N
    Rinsho Byori; 2003 Sep; 51(9):839-46. PubMed ID: 14560650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.